Showing 481-490 of 3494 results for "".
- Study Shows Racial Differences in Pseudofolliculitis Barbae Complications, Treatment Timinghttps://practicaldermatology.com/news/racial-differences-in-pfb-complications-treatment-timing-highlight-care-gaps/2487632/A multicenter retrospective cohort study published as a Letter to the Editor in the Journal of Drugs in Dermatology found that Black patients with pseudofolliculitis barbae (PFB) experienced significantly higher rates of post-inflammatory hyperpigmentation (PIH) and hypertrophic scarring
- Letter Questions Strength of Evidence Linking Hair Relaxers to Uterine Cancerhttps://practicaldermatology.com/news/letter-questions-strength-of-evidence-linking-hair-relaxers-to-uterine-cancer/2487618/A recently published Letter to the Editor in the Journal of Drugs in Dermatology urged clinicians to interpret the growing body of research examining chemical hair relaxers and uterine cancer with caution, arguing that important methodological limitations prevent current evidence from es
- Skin of Color Still Underrepresented Across Major Dermatology Image Searcheshttps://practicaldermatology.com/news/skin-of-color-still-underrepresented-across-major-dermatology-image-searches/2487573/Skin of Color (SOC) remains significantly underrepresented in image search results across major search engines, according to a recent Letter to the Editor published in the Journal of Drugs in Dermatology. Investigators building on earlier research in the area evaluated the first 5
- Analysis Shows Long-Term Cost Impact of Psoriasis and Psoriatic Arthritishttps://practicaldermatology.com/news/analysis-highlights-long-term-cost-impact-of-psoriasis-and-psoriatic-arthritis/2487486/New research published in Dermatology and Therapy suggests the economic burden associated with psoriasis and psoriatic arthritis extends far beyond the diseases themselves and may reach hundreds of billions of dollars over a lifetime. Psoriatic Disease Comorbidities Drive Signifi
- FDA Expands Dupilumab CSU Indication to Children as Young as 2 Yearshttps://practicaldermatology.com/news/dupilumab-approval-expanded-to-include-children-as-young-as-2-years-with-csu/2487479/The US Food and Drug Administration (FDA) has expanded the indication for dupilumab (Dupixent; Sanofi and Regeneron) to include pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. The label expansion, according
- Review: Emerging Therapies Expand Options for Patients With Genodermatoseshttps://practicaldermatology.com/news/review-emerging-therapies-expand-options-for-patients-with-genodermatoses/2487464/A new review published in the Journal of Drugs in Dermatology spotlighted recent advances in the diagnosis, classification, and treatment of several common genodermatoses, incl
- FDA Approves EBGLYSS 8-Week Dosings in Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-ebglyss-8-week-dosings-in-atopic-dermatitis/2487424/The US Food and Drug Administration (FDA) has approved an every-8-week maintenance dosing regimen for EBGLYSS® (lebrikizumab-lbkz) in adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis, according to an
- FDA Adds Bemotrizinol to OTC Sunscreen Monograph in First New UV Filter in Over 20 Yearshttps://practicaldermatology.com/news/fda-adds-bemotrizinol-to-otc-sunscreen-monograph-in-first-new-uv-filter-in-over-20-years/2487644/The US Food and Drug Administration (FDA) has finalized an administrative order adding bemotrizinol as a permitted active ingredient in over-the-counter (OTC) sunscreen products, marking the first addition of a new sunscreen active ingredient to the OTC sunscreen m
- Study: Mineral Sunscreen Whitening Linked to Reduced Application and Protectionhttps://practicaldermatology.com/news/study-links-mineral-sunscreen-whitening-to-reduced-application-and-protection/2487379/New research published in the Journal of Drugs in Dermatology indicates mineral sunscreens produced visible whitening across all skin tones, with a pronounced effect in darker skin tones. Investigators evaluated 5 mi
- Review: Botulinum Toxin Shows Potential in Acne Treatmenthttps://practicaldermatology.com/news/systematic-review-highlights-botulinum-toxins-potential-in-acne-treatment/2487204/Botulinum toxin A may offer a potential adjunctive treatment option for both acne vulgaris and acne scarring, according to a recent systematic review published in the Journal of Drugs in Dermatology. Botulinum Toxin S